Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor

Douglas G. Johns(Merck & Co., Inc., Rahway, NJ, USA (United States)), Harold B. Wood(Merck & Co., Inc., Rahway, NJ, USA (United States)), Thomas J. Tucker(MACOM (United States)), Hratch J. Zokian(MACOM (United States)), S. Aubrey Stoch(MACOM (United States)), Jeffrey T. Kuethe(MACOM (United States)), Fa‐Xiang Ding(MACOM (United States)), Kenneth A. Koeplinger(MACOM (United States)), Inne Crèvecoeur(MACOM (United States)), Louis‐Charles Campeau(Merck & Co., Inc., Rahway, NJ, USA (United States)), Paul G. Bulger(MACOM (United States)), Danila Branca(IRBM Science Park), Anita Y. H. Lee(MACOM (United States)), Petr Váchal(MACOM (United States)), H. Susan Zhou(Worcester Polytechnic Institute), Tjerk Bueters(MACOM (United States)), Dennis Wolford(MACOM (United States)), Sookhee Ha(MACOM (United States)), Eseng Lai(Merck & Co., Inc., Rahway, NJ, USA (United States)), Edward A. O’Neill(MACOM (United States)), Jennifer M. Johnston(San Jose State University), Yan Guo(MACOM (United States)), Y. Xu(MACOM (United States)), Eunkyung A. Kauh(MACOM (United States)), An Bautmans(MACOM (United States)), Bram Volckaert(SGS (Belgium)), R. M. Garbaccio(Merck & Co., Inc., Rahway, NJ, USA (United States)), Frederic P. Vanhoutte(SGS (Belgium)), Puja Banka(MACOM (United States)), Kristien Van Dyck(MACOM (United States)), Abbas M. Walji(MACOM (United States)), Anilkumar G. Nair(MACOM (United States)), Elisabetta Bianchi(IRBM Science Park), David A. Thaisrivongs(MACOM (United States)), Tian Zhao(MACOM (United States)), Xiaohong Zhu(MACOM (United States)), Li Li(China Pharmaceutical University), Dan Zhou(Wuhan University), Erik D. Guetschow(MACOM (United States)), Christine L. Lanning(MACOM (United States)), Hubert Josien(Merck & Co., Inc., Rahway, NJ, USA (United States))
Circulation
May 1, 2023
Cited by 141


Related Papers